QIAGEN NV Form 6-K September 22, 2009 Table of Contents

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 6-K

**Report of Foreign Private Issuer** 

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September, 2009

**Commission File Number 0-28564** 

# QIAGEN N.V.

(Translation of registrant s name into English)

Spoorstraat 50

## Edgar Filing: QIAGEN NV - Form 6-K

## 5911 KJ Venlo

#### The Netherlands

#### (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F <u>X</u> Form 40-F \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes \_\_\_\_\_ No \_X\_\_\_

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

## QIAGEN N.V.

Form 6-K

## TABLE OF CONTENTS

Item Other Information	Page 3
Signatures	4
Exhibit Index	5

#### **OTHER INFORMATION**

On July 30, 2007, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) announced the successful completion of its acquisition of Digene Corporation (Nasdaq: DIGE). QIAGEN completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of QIAGEN. Following the completion of the merger, Digene became a wholly owned subsidiary of QIAGEN s subsidiary QIAGEN North American Holdings, Inc. This report on Form 6-K is intended to furnish certain historical pre-acquisition audited financial statements of Digene. More current information relating to the acquired business and to QIAGEN s financial information subsequent to the acquisition are included in reports on Form 6-K and Form 20-F of QIAGEN.

2	
5	

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

By: /s/ Roland Sackers Roland Sackers Chief Financial Officer

Date: September 22, 2009

## EXHIBIT INDEX

Exhibit No.	Exhibit
99.1	Audited Consolidated Financial Statements of Digene Corporation
	Report of Independent Registered Public Accounting Firm Consolidated Balance Sheets Consolidated Statements of Operations Consolidated Statements of Stockholders Equity Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements
99.2	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Digene Corporation

#### Exhibit 99.1

## FINANCIAL STATEMENTS

## DIGENE CORPORATION

## INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm	2
Consolidated balance sheets at June 30, 2007 and 2006	3
Consolidated statements of operations for each of the three years in the period ended June 30, 2007	4
Consolidated statements of stockholders equity for each of the three years in the period ended June 30, 2007	5
Consolidated statements of cash flows for each of the three years in the period ended June 30, 2007	6
Notes to consolidated financial statements for each of the three years in the period ended June 30, 2007	7

#### REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Supervisory Board and Shareholders of

QIAGEN N.V. and Subsidiaries

We have audited the accompanying consolidated balance sheets of Digene Corporation (the Company ) as of June 30, 2006 and 2007, and the related consolidated statements of operations, stockholders equity, and cash flows for each of the three years in the period ended June 30, 2007. These financial statements are the responsibility of the Company s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Digene Corporation at June 30, 2006 and 2007, and the consolidated results of its operations and its cash flows for each of the three years in the period ended June 30, 2007, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 2 to the financial statements, effective July 1, 2005 the Company changed its method of accounting for share-based compensation.

McLean, Virginia

/s/ Ernst & Young LLP

November 20, 2007

## DIGENE CORPORATION

## CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	June 30,		
ASSETS	2006	2007	
Current assets:			
Cash and cash equivalents	\$ 24,004	\$ 47,880	
Short-term investments	115,253	159,056	
Accounts receivable, less allowance of approximately \$363 and \$441 at June 30, 2006 and 2007, respectively	27,665	35,785	
Inventories, net	6,307	10,681	
Prepaid expenses and other current assets	3,718	3,515	
Deferred tax asset, current	4,275	5,411	
Total current assets	181,222	262,328	
Property and equipment, net	33,935	41,483	
Deposits and other assets	5,981	5,020	
Deferred tax asset, less current portion	10,748	11,977	
Total assets	\$ 231,886	\$ 320,808	
LIABILITIES AND STOCKHOLDERS EQUITY			
Current liabilities:			
Accounts payable	\$ 10,716	\$ 28,042	
Accrued expenses	11,030	10,251	
Accrued payroll	11,190	18,401	
Current portion of long-term debt and lease obligation	1,445	1,895	
Total current liabilities	34,381	58,589	
Deferred rent	246	306	
Long-term debt, less current portion	450	330	
Lease obligation, less current portion	19,323	21,986	
Minority interest	440	540	
Stockholders equity:			
Preferred Stock, \$0.10 par value, 1,000,000 shares authorized, no shares issued and outstanding			
Common Stock, \$0.01 par value, 50,000,000 shares authorized, 23,243,586 and 24,568,779 shares issued and	232	246	
outstanding at June 30, 2006 and 2007, respectively Additional paid-in capital	229,996	240	
Additional paid-in capital Accumulated other comprehensive income	229,996	285,904	
Accumulated deficit	(53,874)	(46,692)	
Total stockholders equity	177.046	239.057	
Total liabilities and stockholders equity	\$ 231,886	\$ 320,808	

See accompanying notes.

## Edgar Filing: QIAGEN NV - Form 6-K

## DIGENE CORPORATION

## CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for per share data)

	2005	e 30, 2007		
Revenues:				
Product sales	\$ 113,21		\$ 150,828	\$ 202,495
Other	1,92	3	2,060	2,126
Total revenues	115,14	2	152,888	204,621
Costs and expenses:				
Cost of product sales	20,12		21,888	26,737
Royalty and technology	5,39		7,572	10,538
Research and development	12,96	4	17,922	26,246
Selling and marketing	45,93	3	62,815	70,407
General and administrative	20,26	5	26,294	58,436
Patent litigation settlements	21,50	0		
Total costs and expenses	126,18	4	136,491	192,364
Income (loss) from operations	(11,04	2)	16,397	12,257
Other income (expense):				
Interest income	80	8	3,808	8,638
Interest expense		7)	(803)	(1,633)
Other income (expense)	(11		(48)	274
	,	- /	(-)	
Total other income (expense)	65	5	2,957	7,279
Income (loss) from operations before minority interest and provision for (benefit from) income taxes	(10,38	7)	19,354	19,536
Minority Interest	(35	(3)	(142)	(156)
Income (loss) from operations before income taxes	(10,74	0)	19,212	19,380
Provision for (benefit from) income taxes	(2,57	'3)	10,773	12,198
Net income (loss)	\$ (8,16	7)	\$ 8,439	\$ 7,182
Basic net income (loss) per share	\$ (0.4	1)	\$ 0.39	\$ 0.30
Diluted net income (loss) per share	\$ (0.4	1)	\$ 0.38	\$ 0.29
Weighted average shares outstanding	10.04	5	01-760	02.050
Basic	19,96	0	21,769	23,950
Diluted	19,96	5	22,215	24,463

See accompanying notes.

## Edgar Filing: QIAGEN NV - Form 6-K

## DIGENE CORPORATION

## CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

(in thousands)

	Common Stock				Accumulated						
			Additional			(	Other			Т	otal
	Shares	Amount	Paid-In Capital		red Stock pensation	I	orehensive acome	Ac	cumulated Deficit		holders uity
Balance at June 30, 2004	19,884	\$ 198	\$ 139,637	\$	(163)	\$	537	\$	(54,146)	\$8	86,063
Comprehensive loss:											
Foreign currency translation							37				37
Unrealized gain on available for-sale											
securities, net of income tax benefit of											
\$33							27				27
Net loss									(8,167)	(	(8,167)
Comprehensive loss										(	(8,103)
Exercise of Common Stock options	153	2	1,530								1,532
Compensatory stock options earned by			,								,
non-employees			(253)		163						(90)
I State			( )								()
Balance at June 30, 2005	20,037	\$ 200	\$ 140,914	\$		\$	601	\$	(62,313)	\$ 7	79,402
Comprehensive income:											
Foreign currency translation							220				220
Unrealized loss on available for-sale											
securities, net of income tax benefit of											
\$109							(129)				(129)
Net income									8,439		8,439
									,		,
Comprehensive income											8,530
Exercise of Common Stock options	907	9	16,711								6,720
Public offering of Common Stock	2,300	23	60,056								50,079
Tax benefit from stock-based	_,		,								
compensation in excess of book											
deductions			6.634								
			0,051			concop					